ReviewJournal of carcinogenesis2014
Targeted therapy for renal cell carcinoma: The next lap.
Review in Journal of carcinogenesis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Article
- Expression of TXNIP is associated with angiogenesis and postoperative relapse of conventional renal cell carcinoma.Scientific reports · 2021Article
- Development of Taccalonolide AJ-Hydroxypropyl-β-Cyclodextrin Inclusion Complexes for Treatment of Clear Cell Renal-Cell Carcinoma.Molecules (Basel, Switzerland) · 2020Article
- Biological Evaluation of Oxindole Derivative as a Novel Anticancer Agent against Human Kidney Carcinoma Cells.Biomolecules · 2020Article
- Long non-coding RNA TCL6 enhances preferential toxicity of paclitaxel to renal cell carcinoma cells.Journal of Cancer · 2020Article
- RCC Immune Microenvironment Subsequent to Targeted Therapy: A Friend or a Foe?Frontiers in oncology · 2020Review
- Knockdown of Pyruvate Kinase M2 Inhibits Cell Proliferation, Metabolism, and Migration in Renal Cell Carcinoma.International journal of molecular sciences · 2019Article
- Patient-derived xenograft models to optimize kidney cancer therapies.Translational andrology and urology · 2019Review
- Limitations to the Therapeutic Potential of Tyrosine Kinase Inhibitors and Alternative Therapies for Kidney Cancer.Ochsner journal · 2019Review
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.Oncogene · 2016Article
- Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions.SpringerPlus · 2016Article
- [Molecular biological foundation of targeted therapy for metastatic renal cell carcinoma].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2016Review
- The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis.Stem cell reviews and reports · 2015Review
- Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma.British journal of cancer · 2015Article
- Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.Journal of medicine and lifeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in rationally targeted therapeutics over the last decade have transformed the clinical care of advanced kidney cancer. While oncologists consolidate the gains of the wave of new agents, comprising a panoply of anti-vascular endothelial growth factor multi-targeted tyrosine kinase inhibitors and inhibitors of the mammalian target of rapamycin (mTOR), there is an increasing sense that a plateau has been reached in the short term. It is sobering that all currently approved targeted therapies have not yielded durable remissions and remain palliative in intent. In the context of recent insights in kidney cancer biology, we review promising ongoing and future approaches for kidney cancer therapeutics aimed toward forging new paths in the systemic management of renal cell carcinoma. Broadly, candidate agents for such innovative strategies include immune check-point inhibitors, anti-cancer stem cell agents, next-generation anti-vascular endothelial growth factor receptor and anti-mTOR agents as well as more investigational agents in the preclinical and early clinical development settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.